Atea Pharmaceuticals, Inc.
AVIRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 13, 2026 | Morgan Stanley | $7.00(+38%) | $5.06 | TheFly | |
| Mar 9, 2026 | Evercore ISI | $10.00(+63%) | $6.15 | TheFly | |
| Aug 12, 2024 | Morgan Stanley | Matthew Harrison | $6.88(+105%) | $3.35 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Morgan Stanley | maintain | Equal Weight | Aug 13, 2026 |
| Evercore ISI Group | maintain | Outperform | Mar 9, 2026 |
| Morgan Stanley | maintain | Equal Weight | Apr 11, 2025 |
| Morgan Stanley | upgrade | Underweight →Equal Weight | Aug 13, 2024 |
| JP Morgan | downgrade | Neutral →Underweight | Aug 10, 2023 |
| JP Morgan | maintain | Neutral | Mar 16, 2023 |
| SVB Leerink | maintain | Market Perform | Jan 27, 2023 |
| Morgan Stanley | maintain | Underweight | Jan 24, 2023 |
| Morgan Stanley | maintain | Underweight | Aug 15, 2022 |
| JP Morgan | maintain | Neutral | Mar 2, 2022 |
| SVB Leerink | maintain | Market Perform | Mar 1, 2022 |
| SVB Leerink | maintain | Market Perform | Feb 16, 2022 |
| Morgan Stanley | downgrade | Equal Weight →Underweight | Jan 6, 2022 |
| SVB Leerink | downgrade | Outperform →Market Perform | Nov 18, 2021 |
| SVB Leerink | maintain | Outperform | Oct 20, 2021 |
| JP Morgan | downgrade | Overweight →Neutral | Oct 20, 2021 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Oct 5, 2021 |
| SVB Leerink | maintain | Outperform | Sep 9, 2021 |
| Morgan Stanley | maintain | Overweight | Aug 18, 2021 |
| Morgan Stanley | maintain | Overweight | Jun 3, 2021 |
| Morgan Stanley | maintain | Overweight | Apr 6, 2021 |
| JP Morgan | maintain | Overweight | Jan 29, 2021 |
| Evercore ISI Group | maintain | Outperform | Nov 25, 2020 |
| Morgan Stanley | maintain | Overweight | Nov 24, 2020 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.41 | $-0.56 | — | $33.0M |
| May 12, 2026 | $-0.57 | $-0.60 | — | $22.4M |
| Mar 5, 2026 | $-0.57 | $-0.49 | — | $1.5M |
| Nov 12, 2025 | $-0.53 | $-0.46 | — | — |
| Aug 7, 2025 | $-0.44 | $-0.46 | — | — |
| May 12, 2025 | $-0.40 | $-0.56 | — | — |
| Mar 6, 2025 | $-0.40 | $-0.35 | — | — |
| Nov 7, 2024 | $-0.37 | $-0.49 | — | — |
News
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2026, and to provide a business update.
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Septembe…
BlackRock Inc. purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 8,720,077 shares of the company's stock, valued at approximately $40,548,000. BlackRock Inc. owned about 10.90% of Atea Pharmaceuticals as of its
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV